A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers. A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 ...
Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results